Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Potential Patchwork Of Local Drug Take-Back Programs Poses Problem For OTC Firms

This article was originally published in The Tan Sheet

Executive Summary

CHPA backs litigation challenging drug take-back requirements to help stave off a patchwork of similar programs. Consumer education requires “a long-term commitment and won't be cheap,” but the OTC industry “can push back against more onerous mandates, says CHPA chief Scott Melville.

You may also be interested in...



CHPA Optimistic Voluntary Drug Takeback Efforts Will Stall Spread Of Mandates

OTC industry trade groups will more aggressively push for an education program to encourage proper disposal of Rx and OTC drugs as states consider mandating industry-funded takeback programs and a patchwork of local ordinances expands.

CHPA Optimistic Voluntary Drug Takeback Efforts Will Stall Spread Of Mandates

OTC industry trade groups will more aggressively push for an education program to encourage proper disposal of Rx and OTC drugs as states consider mandating industry-funded takeback programs and a patchwork of local ordinances expands.

State Officials Urging Rx Pseudoephedrine Face Strong Lobby

Officials from Mississippi, Missouri, Oregon and South Carolina and the National Narcotics Officers Associations Coalition testifying before a House subcommittee call for moving all PSE products to prescription status.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS107563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel